Compare ITGR & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITGR | RLAY |
|---|---|---|
| Founded | 1970 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.1B |
| IPO Year | 2000 | 2020 |
| Metric | ITGR | RLAY |
|---|---|---|
| Price | $126.50 | $18.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $91.14 | $19.50 |
| AVG Volume (30 Days) | 784.0K | ★ 2.2M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $1,853,637,000.00 | $15,355,000.00 |
| Revenue This Year | $1.69 | N/A |
| Revenue Next Year | $6.53 | $324.03 |
| P/E Ratio | $107.18 | ★ N/A |
| Revenue Growth | 7.98 | ★ 53.44 |
| 52 Week Low | $62.00 | $3.89 |
| 52 Week High | $126.14 | $21.27 |
| Indicator | ITGR | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 79.42 | 43.70 |
| Support Level | $124.84 | $18.02 |
| Resistance Level | $126.14 | $20.82 |
| Average True Range (ATR) | 0.26 | 0.87 |
| MACD | -1.10 | -0.24 |
| Stochastic Oscillator | 85.61 | 21.00 |
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns maximum of its revenue in the United States, and also has its presence in Ireland, Puerto Rico, Costa Rica, and Rest of the World.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.